• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen to terminate participation in co-development and commercialization of brodalumab

    Amgen to terminate participation in co-development and commercialization of brodalumab

  2. UPDATE: Here's another way to spot potential health-care-stock winners

    UPDATE: Here's another way to spot potential health-care-stock winners

  3. Amgen Announces Voting Results of Annual Meeting of Stockholders

    Amgen Announces Voting Results of Annual Meeting of Stockholders

  4. Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine

    Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine

  5. Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

    Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

  6. Amgen Ends Psoriasis-Drug Partnership With AstraZeneca

    Amgen Ends Psoriasis-Drug Partnership With AstraZeneca

  7. Research and Markets: Global Cat Allergy Pipeline Review 2015

    Research and Markets: Global Cat Allergy Pipeline Review 2015

  8. Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

    Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

  9. Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference

    Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference

  10. Research and Markets: Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

    Research and Markets: Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.